Related Experiment Video
Updated: May 26, 2026

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
Published on: August 17, 2022
Prognostic Implications of Coronary Microvascular Dysfunction in ST-Elevation Myocardial Infarction by Obesity Status
Qian Guo1, Yingying Guo2, Shutian Shi1
1Division of Cardiology, Beijing Anzhen Hospital, National Clinical Research Center for Cardiovascular Diseases, Capital Medical University, Beijing, China.
Aims:
This study aimed to assess the association of coronary microvascular dysfunction (CMD) assessed by the angiography-derived index of microcirculatory resistance (angio-IMR) with long-term cardiovascular outcomes in ST-elevation myocardial infarction (STEMI) patients stratified by obesity categories.
Materials And Methods:
In this multicentre prospective cohort, STEMI patients undergoing primary percutaneous coronary intervention (PPCI) were enrolled. Patients were stratified by obesity categories (healthy weight: BMI < 24 kg/m2; overweight: 24-28 kg/m2; obesity: ≥ 28 kg/m2). CMD was defined as angio-IMR > 40 U.
Results:
Of 497 STEMI patients, CMD prevalence was comparable across BMI groups (p = 0.875). The cumulative incidence of MACCE was significantly higher in the CMD group than in the non-CMD group among patients with obesity (33.3% vs. 15.0%, log-rank p = 0.016), but not among those with overweight (19.6% vs. 15.9%, log-rank p = 0.565) and healthy weight (20.7% vs. 17.4%, log-rank p = 0.673). CMD independently predicted MACCE in obesity (adjusted HR; p = 0.020), with consistent results for continuous angio-IMR (adjusted HR 1.03, p < 0.001). No associations existed in patients with overweight or healthy weight. Additionally, CMD was associated with a higher prevalence of intramyocardial haemorrhage exclusively in obesity (adjusted OR 4.40, p = 0.003) and overweight (adjusted OR 2.65, p = 0.007).
Conclusion:
CMD assessed by angio-IMR is an independent predictor of MACCE in STEMI patients with obesity, but not those without obesity. Patients with obesity and STEMI who have CMD may represent a high-risk subgroup for future trials of microvascular-protective therapies.
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Drug Dosing: Obese Patients
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
